Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

we and Pfizer elect to pursue that option.
  • Plan to initiate enrollment next month in our Phase 3 CONCERT trial, a 12-month safety and efficacy study evaluating Dimebon in combination with donepezil (Aricept(R)) in approximately 1,000 patients with mild-to-moderate Alzheimer's disease.
  • Plan to initiate two additional Phase 3 studies in 2009 that will evaluate Dimebon in a total of approximately 1,100 patients with moderate-to-severe Alzheimer's disease.
  • Huntington's Disease

    • Held an end-of-Phase 2 meeting at which the U.S. Food and Drug Administration (FDA) informed us that we could begin a Phase 3 trial of Dimebon in patients with Huntington's disease using the Mini-Mental State Examination (MMSE) and the Clinician's Interview-based Impression of Change, plus caregiver input (CIBIC-plus) as co-primary endpoints. Discussions with the European regulators are ongoing. We expect to begin this study in 2009.
    • Presented the data from the Phase 2 trial of Dimebon in Huntington's disease patients at the 9th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) held last week. Results showed Dimebon to be well tolerated and to significantly improve cognition as measured by the MMSE.

    Mechanism of Action (MOA)

    • Presented new data at various medical conferences, including the recent AD/PD conference, that provide additional evidence that Dimebon potentially stabilizes and improves mitochondrial function in a way that prevents neuron death and dysfunction, a mechanism thought to be distinct from currently available Alzheimer's disease medications.
    • At AD/PD, we presented new research from the Karolinska Institutet, which quantified the impact of Dimebon on mitochondrial function. Responses were seen on mitochondria
      '/>"/>

    SOURCE Medivation, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
    2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
    3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
    4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
    5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
    6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
    7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
    8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
    9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
    10. Medivation Announces Participation in Upcoming Conferences
    11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
    (Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
    (Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
    (Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
    Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
    ... May 9, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... or "AOB"), a pharmaceutical company dedicated to improving ... a broad range of prescription and over–the-counter ("OTC") ... quarter ended March 31, 2011. ...
    ... Fla., May 9, 2011 Dyadic International, Inc. ... focused on the discovery, development, manufacture and sale ... industrial enzyme and biopharmaceutical industries, today announced that ... and development center in The Netherlands, will be ...
    ... 9, 2011 Ardea Biosciences, Inc. (Nasdaq: ... of small-molecule therapeutics for the treatment of serious diseases, ... first quarter ended March 31, 2011. "Results from our ... with allopurinol demonstrate lesinurad,s potential to bring relief to ...
    Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2011 Financial Results 2American Oriental Bioengineering Reports First Quarter 2011 Financial Results 3American Oriental Bioengineering Reports First Quarter 2011 Financial Results 4American Oriental Bioengineering Reports First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 6
    (Date:4/23/2014)... group decision increases with the abundance of brains involved ... variety of factors as often happens in life ... groups actually tend to make more accurate decisions while ... pieces of information. , The findings present a significant ... the "wisdom of crowds," wherein individual observations even ...
    (Date:4/23/2014)... newly coined term for novels and films which focus on ... Copenhagen shows how these fictions serve as a mental laboratory ... change and imagine other living conditions. , "Global warming ... atmosphere; it is also a cultural phenomenon in which meaning ... films we see. And there are so many of them ...
    (Date:4/23/2014)... HOUSTON, April 23, 2014 A biomedical engineer at ... highly innovative technology to make blood transfusions safer. His ... the National Institutes of Health (NIH). , Blood ... one of modern medicine,s absolute necessities. Without them, for ... mean transfusions are perfect, however. There,s strong evidence that ...
    Breaking Biology News(10 mins):Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
    ... More than 450 world experts from 60 countries will ... DNA "barcoding" - a rapidly growing international initiative to develop ... Earth. The Fourth International Barcode of Life Conference ... from Wednesday 30 November to Saturday 3 December. ...
    ... years ago, two teams of explorers raced to be the first ... South Pole on December 14, 1911. , Thirty-three days later ... Falcon Scott arrived at the Pole in second place. At ... by Douglas Mawson was searching for the South Magnetic Pole. ...
    ... surface of an implant such as a new hip or ... and researchers at the University of Gothenburg, Sweden, can now ... are presented in the International Journal of Nanomedicine . ... of the most common reasons for an implant being rejected," ...
    Cached Biology News:Seaweed hotspots, illegal logging, and discovering new species under the desert 2Seaweed hotspots, illegal logging, and discovering new species under the desert 3Seaweed hotspots, illegal logging, and discovering new species under the desert 4Climate change stunting growth of century-old Antarctic moss shoots 2Cobblestones fool innate immunity 2
    APG5 autophagy 5-like (S. cerevisiae)...
    ...
    Griess Reagent component for determination of nitrite in aqueous solutions....
    ... terminators, template DNA, primers, salts or other ... have proved critical for both standard and ... work with dye terminator cycle sequencing chemistries ... unique uniformity of the magnetic paeticles guarantees ...
    Biology Products: